A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Trial Profile

A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Aug 2017

At a glance

  • Drugs DP 001 (Primary)
  • Indications Secondary hyperparathyroidism
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Deltanoid Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 14 Oct 2015 According to a Deltanoid Pharmaceuticals media release, results from this study will be presented at the American Society of Nephrology meeting.
    • 04 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top